Palo Alto Networks (NYSE:PANW) is scheduled report FYQ4 results on 8/30, after the market close. After reading some of the publicly available earnings previews out there, which I think are highly dissatisfactory, I decided to write my own for the benefit of the retail investor. I hope this preview will help you gain more insight into the key debate points going into PANW’s earnings and also....More>>>
Buffett sold a large portion of his stake in Munich Re (HAM:MUV2) in 2015 citing a terrible outlook for the reinsurance business. A year and a half later, it’s clear he would have made continued to profit on the stock if he had held it, but it is unclear how long that will last and whether his vision is still to come true.
The CEO of Berkshire Hathaway (BRK.A)(BRK.B) held more than....More>>>
Gilead Sciences (GILD) is lower in after hours trading, after its first-quarter earnings came up short.
The company said it earned $3.03 a share on revenue of $7.79 billion.
Analysts were expecting earnings of $3.13 a share on revenue of $8.07 billion.
The companys guidance for the full year was also light. It said it expects revenue between $30....More>>>
Making an investment case for Tesla Motors Inc (NASDAQ:TSLA) is not that difficult. One only needs to look toward the future. Autonomous vehicles, connected cars, and cleaner/renewable energy are expected to be strong growth drivers in the years ahead. And those are two of Tesla’s main business segments. TSLA stock, then, should be in good hands.
Dolby Laboratories (NYSE:DLB) is a compelling growth story. The stock is currently hovering around $46, but new growth drivers can send it above $60 this year. The age-old surround-sound provider that develops sound for almost everything related to entertainment, right from movie theaters to TV sets to computers and to your car, generates income by earning royalties via licensing its surround-sound....More>>>
My Top Pick for speculators for the coming year is a biotech company, explains leading growth and income stock specialist Crista Huff, editor of Cabot Undervalued Stocks Advisor.
Vertex Pharmaceuticals (VRTX) is prominent for its world-leading treatments for cystic fibrosis. Vertex is expected to outperform its peers in earnings growth through 2020.
Vertex is expected to report earnings....More>>>
The U.S. economy is expected to strengthen next year, in part because of the government stimulus proposed at by President-elect Donald Trump, but job growth is likely to slow as the recovery approaches its eighth anniversary, according to a recent survey of economists.
The economy is projected to grow at a 2.3% annual rate in 2017, up from an estimated 1.6% this year, according to the average....More>>>